A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Pulmonary Hypertension · Heart Failure With Preserved Ejection Fraction
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 191 (planned)
- Started
- Sep 4, 2024
- Main results expected
- Nov 24, 2026
- Fully finished
- Jan 5, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Mean change from baseline in Pulmonary Vascular Resistance (PVR) in participants with a combined pre- and post-capillary pulmonary hypertension (CpcPH).
Measured over: Baseline up to Week 24 post first dose
Assess safety of TX000045 by the incidence of adverse events, adverse events of special interest and SAEs.
Measured over: Baseline up to Week 30 post first dose
Number of participants with abnormal laboratory values and/or adverse events that are related to treatment.
Measured over: Baseline up to Week 30 post first dose
Number of participants with treatment-related adverse events.
Measured over: Baseline up to Week 30 post first dose
Number of participants with changes in the physical examination findings.
Measured over: Baseline to Week 30 post first dose
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06616974 · record last updated 2026-07-07 · checked 2026-11-09 15:47 UTC